Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies.
Gene therapy is a therapeutic approach that is designed to correct specific molecular defects that contribute to the cause or progression of cancer. Genes that are mutated or deleted in cancers include the cancer susceptibility genes p53 and BRCA1. Because mutational inactivation of gene function is specific to tumor cells in these settings, cancer gene correction strategies may provide an opportunity for selective targeting without significant toxicity for normal nontumor cells. Both p53 and BRCA1 appear to inhibit cancer cells that lack mutations in these genes, suggesting that the so-called gene correction strategies may have broader potential than initially believed. Increasing knowledge of cancer genetics has identified these and other genes as potential targets for gene replacement therapy. Initial patient trials of p53 and BRCA1 gene therapy have provided some indications of potential efficacy, but have also identified areas of basic and clinical research that are needed before these approaches may be widely used in patient care.
Obermiller
P S
PS
Vanderbilt University Cancer Center, 2220 Pierce Avenue South, Nashville, TN 37232, USA.
Tait
D L
DL
Holt
J T
JT
D019313:BRCA1 Protein / Q000235:genetics; D001943:Breast Neoplasms / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D019313:BRCA1 Protein; D016159:Tumor Suppressor Protein p53